ImmuneSensor_Resize.png
ImmuneSensor Therapeutics Granted New U.S. Patent for its Oral cGAS Inhibitors
September 17, 2024 08:00 ET | ImmuneSensor Therapeutics
Composition and methods patent granted claims covering compounds for treating broad range of inflammatory and autoimmune diseases and built on foundational intellectual property for the discovery of...
BioAegis Therapeutics LOGO 2.5 x 5 150 pixel.jpg
BioAegis Therapeutics to Present at Upcoming MedInvest Biotech & Pharma Investor Conference in NYC
September 12, 2024 16:56 ET | BioAegis Therapeutics
NORTH BRUNSWICK, N.J., Sept. 12, 2024 (GLOBE NEWSWIRE) -- BioAegis Therapeutics, a pioneering biotech company at the forefront of innovative therapies for inflammatory diseases, announces that its...
GMILogo_Vertical-Gradient.png
Arachidonic Acid Market to Reach $308 Mn by 2032, Says Global Market Insights Inc.
August 27, 2024 05:40 ET | Global Market Insights Inc.
Selbyville, Delaware, Aug. 27, 2024 (GLOBE NEWSWIRE) -- The arachidonic acid market will be worth USD 308 million by 2032, as reported in a research study by Global Market Insights Inc. The...
Derm logo.png
Derm-Biome Pharmaceuticals to develop skincare treatment that promotes skin health and longevity
August 13, 2024 10:00 ET | Derm-Biome Pharmaceuticals, Inc
VANCOUVER, British Columbia, Aug. 13, 2024 (GLOBE NEWSWIRE) -- Derm-Biome Pharmaceuticals Inc, a Vancouver-based biopharmaceutical company focused on skin health and healthy aging, is excited to...
Figure 1
NurExone's ExoPTEN, loaded with siRNA, Demonstrates Ability to Target Injury and Inflammation Sites – New Study
August 09, 2024 16:04 ET | NurExone Biologic Inc
NurExone announces promising new data for its ExoPTEN nanodrug, highlighting progress towards commercial-grade manufacturing
Logo 1200x628.jpg
CytoSorbents to Report Second Quarter 2024 Operating and Financial Results
August 07, 2024 07:00 ET | CytoSorbents
CytoSorbents to Report Q2 2024 Financial and Operating Results
NodThera_logo.jpg
NodThera Named a ‘Fierce 15’ Company by Fierce Biotech
August 05, 2024 10:16 ET | NodThera
NodThera Named a ‘Fierce 15’ Company by Fierce Biotech Philadelphia, PA, August 5, 2024 - NodThera, a leading clinical-stage biotech delivering a paradigm shift in the treatment of chronic...
NodThera_logo.jpg
NodThera Announces Appointment of Greg Chow as Chief Financial and Business Officer
August 01, 2024 07:00 ET | NodThera
NodThera Announces Appointment of Greg Chow as Chief Financial and Business Officer Greg brings over 25 years of public and private company leadership experience Philadelphia, PA, August 1, 2024 -...
NodThera_logo.jpg
NodThera’s NLRP3 Inhibitor NT-0796 Meets Primary Endpoint of Inflammation Reversal in Phase Ib/IIa Trial in Obese Subjects with Cardiovascular Risk
June 12, 2024 07:00 ET | NodThera
NodThera Ltd (“NodThera” or the “Company”) NodThera’s NLRP3 Inhibitor NT-0796 Meets Primary Endpoint of Inflammation Reversal in Phase Ib/IIa Trial in Obese Subjects with Cardiovascular Risk ...
Regeneron Logo.jpg
Dupixent® (dupilumab) Recommended for EU Approval by the CHMP to Treat Patients with COPD
May 31, 2024 01:05 ET | Regeneron Pharmaceuticals, Inc.
Recommendation for adults with uncontrolled COPD with raised blood eosinophils based on data from two landmark Phase 3 trials demonstrating Dupixent significantly reduced exacerbations and improved...